Coherus Oncology, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
1.630
-0.060 (-3.55%)
At close: Mar 13, 2026, 4:00 PM EDT
1.650
+0.020 (1.23%)
After-hours: Mar 13, 2026, 7:32 PM EDT
Coherus Oncology Stock Forecast
Stock Price Forecast
The 4 analysts that cover Coherus Oncology stock have a consensus rating of "Strong Buy" and an average price target of $5.51, which forecasts a 238.04% increase in the stock price over the next year. The lowest target is $1.05 and the highest is $10.
Price Target: $5.51 (+238.04%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 22, 2026.
Analyst Ratings
The average analyst rating for Coherus Oncology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Initiates $10 | Buy | Initiates | $10 | +513.50% | Jan 22, 2026 |
| Maxim Group | Maxim Group | Hold → Strong Buy Upgrades $4 | Hold → Strong Buy | Upgrades | $4 | +145.40% | Sep 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +329.45% | Apr 29, 2025 |
| UBS | UBS | Hold Maintains $1.5 → $1.05 | Hold | Maintains | $1.5 → $1.05 | -35.58% | Apr 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +329.45% | Mar 11, 2025 |
Financial Forecast
Revenue This Year
79.57M
from 42.17M
Increased by 88.67%
Revenue Next Year
102.35M
from 79.57M
Increased by 28.64%
EPS This Year
-0.98
from 1.43
EPS Next Year
-0.84
from -0.98
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 102.1M | 143.0M | |||
| Avg | 79.6M | 102.4M | |||
| Low | 60.8M | 31.8M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 142.0% | 79.8% | |||
| Avg | 88.7% | 28.6% | |||
| Low | 44.1% | -60.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.53 | -0.49 | |||
| Avg | -0.98 | -0.84 | |||
| Low | -1.36 | -1.16 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.